Reversing stomach lining changes to lower cancer risk
Part of Digestive system clinical trials.
This trial tests whether a treatment can reverse stomach lining changes called GIM that increase cancer risk. It's for people who have had a past H. pylori infection but no current stomach cancer, and whose GIM has certain high-risk features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with gastric intestinal metaplasia (GIM), a change in your stomach lining.
- Your GIM has at least one high-risk feature, like being widespread, a certain type (incomplete or mixed), or having a family history of stomach cancer.
- You have had H. pylori infection in the past, but you do not have it now.
- You are not currently being treated for active stomach cancer.
- You are not at high risk for bleeding (for example, due to blood thinners or a bleeding disorder) and you are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ursodeoxycholic acid can reverse intestinal metaplasia (a precancerous stomach condition) in patients who have no H. pylori infection. The goal is to see if this medication can help lower the risk of stomach cancer.
This study tests whether berberine, a natural compound, can help reverse or slow the progression of gastric intestinal metaplasia, a precancerous condition in the stomach lining. Participation involves taking the medication and monitoring your stomach health over time.
This study collects health information from people at different stages of stomach cancer risk, including those with precancerous changes, healthy individuals, and those with early stomach cancer. The goal is to better understand and prevent stomach cancer.
This study tests a medicine called pyrvinium to see if it can reverse early changes in the stomach lining that may lead to stomach cancer. It may help prevent stomach cancer from developing.
This trial tests whether a personalized AI program can give you better health advice based on your stomach condition. It is for people who have gastric intestinal metaplasia (GIM) or have had H. pylori infection and are already scheduled for a gastroscopy.
This trial looks at adults with stomach lining changes—either atrophic gastritis or intestinal metaplasia—and studies how to predict who may be at risk for stomach cancer. It may help earlier identification and closer monitoring for people with these conditions.
Hear when a new Gastric Intestinal Metaplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.